Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jespersen

Showing results (41-50 of 269) with videos related to

Pageof 27
Sort By:
Clinical Chemistry|January 1, 1989
Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin IIIJ Gram, J Jespersen
Thrombosis and Haemostasis|June 30, 1986
Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycleJ Jespersen, C Kluft
Journal of Thrombosis and Haemostasis : JTH|July 15, 2016
Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study: commentJ Skov, J Jespersen
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1984
Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysisT Astrup, J Jespersen
Metabolism: Clinical and Experimental|May 1, 1992
Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patientsJ Gram, J Jespersen
Clinical Chemistry|March 1, 1987
Effects of surfactants or aprotinin on antithrombin III assayJ Gram, J Jespersen
Thrombosis and Haemostasis|August 30, 1985
Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen--levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivatorJ Jespersen, C Kluft
Thrombosis and Haemostasis|April 22, 1985
A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samplesJ Gram, J Jespersen
Nephron|January 1, 1983
Renal diseases, disseminated intravascular coagulation, and antithrombin IIIP Brandt, J Jespersen
Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception|December 1, 1990
Metabolic aspects of oral contraceptives of relevance for cardiovascular disease. First European conference on sex steroids and metabolismS O Skouby, J Jespersen
Pageof 27

Showing results (41-50 of 269) with videos related to

Sort By:
Pageof 27
Clinical Chemistry|January 1, 1989
Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin IIIJ Gram, J Jespersen
Thrombosis and Haemostasis|June 30, 1986
Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycleJ Jespersen, C Kluft
Journal of Thrombosis and Haemostasis : JTH|July 15, 2016
Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study: commentJ Skov, J Jespersen
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1984
Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysisT Astrup, J Jespersen
Metabolism: Clinical and Experimental|May 1, 1992
Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patientsJ Gram, J Jespersen
Clinical Chemistry|March 1, 1987
Effects of surfactants or aprotinin on antithrombin III assayJ Gram, J Jespersen
Thrombosis and Haemostasis|August 30, 1985
Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen--levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivatorJ Jespersen, C Kluft
Thrombosis and Haemostasis|April 22, 1985
A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samplesJ Gram, J Jespersen
Nephron|January 1, 1983
Renal diseases, disseminated intravascular coagulation, and antithrombin IIIP Brandt, J Jespersen
Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception|December 1, 1990
Metabolic aspects of oral contraceptives of relevance for cardiovascular disease. First European conference on sex steroids and metabolismS O Skouby, J Jespersen
Pageof 27